<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="93">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05159934</url>
  </required_header>
  <id_info>
    <org_study_id>MS063</org_study_id>
    <nct_id>NCT05159934</nct_id>
  </id_info>
  <brief_title>Nicotine Differences in Smokers</brief_title>
  <official_title>Nicotine Discrimination in Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this project is to determine the threshold dose of nicotine, which the&#xD;
      smokers will be able to differentiate from placebo (saline). Will use IV pulsed-nicotine&#xD;
      infusion that closely matches nicotine delivery by inhaled tobacco use (i.e., tobacco&#xD;
      cigarette or electronic cigarette), allowing precise and reproducible nicotine delivery. Four&#xD;
      nicotine doses (0.1, 0.05, 0.025, and 0.0125 mg nicotine/pulse) which are within the range of&#xD;
      nicotine doses that are delivered by cigarettes with very low to regular nicotine content.&#xD;
      These doses will be delivered as a cluster of 4 pulsed-nicotine infusions of 2 sec duration&#xD;
      with a 28 sec interval between each dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty participants will have 2 Experimental Session on 2 separate days. Experimental Session&#xD;
      1 will determine if smokers can reliably discriminate 0.1mg nicotine/pulse nicotine from&#xD;
      saline. Experimental Session 2 will determine if smokers can discriminate 0.05, 0.025, and&#xD;
      0.0125 mg nicotine/pulse of nicotine from saline.&#xD;
&#xD;
      Hypothesis: The threshold for discrimination will be 0.05 mg nicotine/pulse and the doses&#xD;
      below that (0.025, and 0.0125 mg nicotine/pulse) will be subthreshold.&#xD;
&#xD;
      Exploratory Aim: To explore the relationship between the threshold for subjective drug&#xD;
      effects and drug discrimination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 5, 2022</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Twenty participants will have 2 Experimental Session on 2 separate days. Experimental Session 1 will determine if smokers can reliably discriminate 0.1mg nicotine/pulse nicotine from saline. Experimental Session 2 will determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Nicotine dose will be prepared by pharmacy</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Effect Questionnaire</measure>
    <time_frame>over 3 hours</time_frame>
    <description>Liking effect</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Nicotine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Experimental Session 2 will determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline will compared to different nicotine doses. Nicotine doses: 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine</intervention_name>
    <description>Determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.</description>
    <arm_group_label>saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline will be use to determine if smokers can discriminate from the nicotine/pulse of nicotine and saline</description>
    <arm_group_label>Nicotine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Female and male smokers, aged 18 to 65 years veterans and non-veterans who have been&#xD;
             smoking tobacco cigarettes for at least a year&#xD;
&#xD;
          -  smoke â‰¥ 5 cigs/day ;&#xD;
&#xD;
          -  urine cotinine levels &gt; 100 ng/mL consistent with nicotine intake of an active smoker&#xD;
             (23)&#xD;
&#xD;
          -  not seeking treatment at the time of the study for nicotine dependence&#xD;
&#xD;
          -  Good health as verified by medical history, screening examination, and screening&#xD;
             laboratory tests&#xD;
&#xD;
          -  For women, not pregnant as determined by pregnancy screening, nor breast feeding, and&#xD;
             using acceptable birth control methods.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of major medical or psychiatric disorders that the physician investigator&#xD;
             deems as contraindicated for the subject to be in the study&#xD;
&#xD;
          -  regular use of psychotropic medication (antidepressants, antipsychotics, or&#xD;
             anxiolytics)&#xD;
&#xD;
          -  current alcohol or substance dependence for any other recreational or prescription&#xD;
             drugs other than nicotine&#xD;
&#xD;
          -  use of e-cigarettes more than 10 days in the past 30 days&#xD;
&#xD;
          -  urine drug screening indicating recent illicit drugs use (with the exception of&#xD;
             marijuana).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehmet Sofuoglu, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mehmet Sofuoglu, M.D.,Ph.D.</last_name>
    <phone>203-932-5711</phone>
    <phone_ext>4809</phone_ext>
    <email>Mehmet.sofuoglu@yale.edu</email>
  </overall_contact>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 2, 2021</study_first_submitted>
  <study_first_submitted_qc>December 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 15, 2021</last_update_submitted>
  <last_update_submitted_qc>December 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Mehmet Sofuoglu</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

